MAPT and Alzheimer disease: Our ultimate goal is to develop various HGF combination therapies (dependent or independent of clinical‐grade hUC‐MSCs) for AD patients, including targeting of the Aβ and tau pathological changes and optimizing the existing regulatory methods for the inflammatory environment, to finally achieve a comprehensive therapy for AD; but all these speculations require further digging and verification, and we plan to explore more in future research.